Lisata Therapeutics Partners with Rhythm Biosciences to Enhance Cancer Risk Prediction Tools

Datma and Rhythm Biosciences Forge Alliance to Enhance Cancer Risk Prediction Tools

In a significant development within the healthcare landscape, datma, a leader in federated real-world data access, announces a strategic partnership with Rhythm Biosciences Ltd. This collaboration aims to enhance the commercialization of Rhythm’s predictive cancer diagnostics, particularly its geneType™ risk assessment portfolio. The partnership seeks to leverage datma's innovative federated data platform, datma.FED, to access high-quality, real-world clinical data. This initiative comes at a crucial time as the demand for genomic-integrated stratification tools grows, necessitating robust data to improve their development and performance.

The fragmented nature of healthcare data often poses challenges, particularly concerning privacy constraints and the complexities involved in data access. Datma.FED effectively addresses these issues by allowing secure, federated access to de-identified data across various healthcare organizations without the need for data centralization or movement. This approach not only safeguards patient privacy but also enhances the reliability of the data utilized in developing risk prediction models. By integrating longitudinal, de-identified clinical data from datma.FED, Rhythm aims to refine its genomic-integrated risk scoring technologies, thereby generating essential clinical utility evidence and health economic models that are critical for engaging healthcare systems.

Noah Nasser, CEO of datma, expresses optimism about the collaboration, pointing to the rising need for secure data access in supporting research and development in diagnostics and therapeutics. Meanwhile, Dr. Erika Spaeth, Director of Clinical Affairs at Rhythm Biosciences, underscores the significance of high-quality data in validating the clinical relevance of their risk prediction tools. This partnership not only represents a pivotal step in advancing Rhythm’s offerings but also positions both companies favorably for future interactions with healthcare systems regarding the implementation of population-based risk stratification tools.

In addition to this collaboration, the healthcare sector increasingly recognizes the importance of data-driven approaches in improving patient outcomes. As genomic medicine continues to evolve, partnerships like that of datma and Rhythm Biosciences exemplify a proactive strategy to harness the potential of real-world data. Such initiatives are integral to the ongoing development of personalized medicine, where tailored treatment plans can be informed by comprehensive risk assessments.

The collaboration highlights a broader trend in the industry, where the integration of advanced data analytics with genomic technologies is expected to play a pivotal role in shaping future healthcare solutions. As both companies work towards enhancing cancer risk prediction capabilities, they contribute to a growing movement that prioritizes innovation and patient-centric care in the face of complex healthcare challenges.